[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618476":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":26,"locations":35,"responsibleParty":57,"collaborators":10,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Royal Brompton & Harefield NHS Foundation Trust","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients to be commenced on anti-fibrotics",null,"Patients with either idiopathic pulmonary fibrosis or progressive pulmonary fibrosis planned to commenced anti-fibrotic medication (either pirfenidone or nintedanib) will be recruited.",[13,14],"Other: No Interventions","Other: No intervention",{"label":16,"type":10,"description":17,"interventionNames":18},"Control group","We will also recruit 20 controls with predominantly fibrotic lung disease. Only those with extent of disease \\> 20% on HRCT as determined by PI and CI will be included. These are patients who in the opinion of the treating physician may require anti-fibrotic treatment in the future, but are not planned to start anti-fibrotic medications over the subsequent 4 months and have not previously been on anti-fibrotic medications.",[13,14],[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"No Interventions","No intervention",[16,9],{"type":6,"name":22,"description":22,"armGroupLabels":25,"otherNames":10},[16,9],[27,32],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Jessica Dr Raja","CONTACT","07955229245","jessica.raja2@nhs.net",{"name":33,"role":29,"phone":10,"phoneExt":10,"email":34},"Elisabetta Professor Renzoni","elisabetta.renzoni@nhs.net",[36],{"facility":37,"status":38,"city":39,"state":10,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Royal Brompton Hospital","RECRUITING","London","SW36NP","United Kingdom","UK",{"type":44,"coordinates":45},"Point",[46,47],-0.12574,51.50853,{"lat":47,"lon":46},[50,51,52,54,56],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":33,"role":29,"phone":10,"phoneExt":10,"email":34},{"name":28,"role":53,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":55,"role":53,"phone":10,"phoneExt":10,"email":10},"Rasleen Kahai",{"name":33,"role":53,"phone":10,"phoneExt":10,"email":10},{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100618476","a-pilot-study-to-assess-body-mass-composition-measurement-using-bia-and-muscle-ultrasound-in-ipf-and-ppf-patients-on-anti-fibrotic-medications-100618476",false,"NCT07332117","A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications","AF-BMC","Inclusion Criteria:\n\n* A diagnosis of Idiopathic pulmonary fibrosis or progressive pulmonary fibrosis\n* Newly commencing anti-fibrotic medication (either nintedanib or pirfenidone)\n* Subject aged \\> 18 years\n* Able to willingly give consent\n\nExclusion Criteria:\n\n* Co-morbidities currently requiring enteral feeding\n* Weight loss \\> 10% in preceding 3-6 months\n* Significant musculoskeletal issues that may impact muscle mass\n* End of life care (expected \\\u003C 6 weeks left to live)\n* Previous anti-fibrotic use\n* Currently on \\> Prednisolone 10mg daily\n* Presence of implantable cardioverter defibrillator (ICD) or permanent pacemaker (PPM)\n* Heart failure\n* Pregnancy","ALL","18 Years",{"count":69,"type":70},30,"ESTIMATED","OBSERVATIONAL","To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound",[74,75],"Idiopathic Pulmonary Fibrosis (IPF)","Progressive Pulmonary Fibrosis",[77,78,79],"bioimpedance analysis","muscle ultrasound","body composition","2025-12-31",{"date":82,"type":83},"2026-01-12","ACTUAL",{"date":85,"type":83},"2025-09-09",{"date":87,"type":70},"2026-04",{"name":5,"class":6},1]